Statute Details
- Title: Human Biomedical Research (Tissue Banking) Regulations 2019
- Act Code: HBRA2015-RG3
- Legislative Type: Subsidiary legislation (SL)
- Authorising Act: Human Biomedical Research Act 2015 (Section 63)
- Commencement: 1 November 2019
- Latest Revised Edition (as provided): 2025 Revised Edition (2 June 2025)
- Status (as provided): Current version as at 27 Mar 2026
- Parts: Part 1 (Preliminary); Part 2 (Tissue Banks Generally); Part 3 (Tissue for Human Tissue Transplantation Research); Part 4 (Miscellaneous)
- Key Provisions (from extract): Section 2 (Definitions); Sections 3–29 (operational, safety, notification, and compliance requirements); First Schedule (Declaration of compliance); Second Schedule (Fees)
- Relevant Website (definition): https://elis.moh.gov.sg/tiaras
What Is This Legislation About?
The Human Biomedical Research (Tissue Banking) Regulations 2019 (“Tissue Banking Regulations”) are Singapore’s detailed regulatory rules for tissue banks that store, process, supply, or export human tissue used in biomedical research. The Regulations sit under the Human Biomedical Research Act 2015 (“HBRA”), translating the Act’s high-level framework into practical obligations for tissue banking operations.
In plain terms, the Regulations are designed to ensure that tissue used for research is handled safely, that donors’ welfare and confidentiality are protected, and that tissue can be traced and recalled if something goes wrong. They also impose administrative duties—such as notifications to the relevant authority and declarations of compliance—so that regulators can monitor tissue banking activities and respond to safety risks.
Although the Regulations focus on “tissue banks generally” (Part 2), they also include a specialised set of requirements for tissue used in “human tissue transplantation research” (Part 3). This reflects the heightened ethical and clinical risks associated with research that involves transplantation or grafting of tissue, even when the tissue is used for research purposes rather than routine clinical care.
What Are the Key Provisions?
1) Core definitions that drive compliance. Section 2 provides definitions that determine when the Regulations apply and how key terms are interpreted. For example, “human tissue transplantation” is defined broadly to include transplantation or grafting within the same person, between parts of the same body, and between individuals. This breadth matters because it can pull certain research activities into Part 3’s more stringent requirements.
Section 2 also defines “principal person in charge designated” for a tissue bank—an individual the tissue bank must designate under the HBRA. It defines “recipient” to include researchers or research institutions receiving tissue from a tissue bank, while excluding the person to whose body the tissue is transplanted or grafted. The Regulations also define “non-identifiable” tissue by reference to the HBRA’s meaning, and define “untoward occurrence” with a detailed list of serious adverse outcomes, including death, life-threatening events, hospitalisation, persistent disability, transmission of communicable disease, misidentification or mix-ups, and congenital anomalies or birth defects.
2) Notification, declarations, and accountability mechanisms. Part 2 contains multiple administrative and governance obligations. These include requirements for notification by a tissue bank (Sections 4 and 5), designation of a principal person in charge (Section 6), and ongoing duties to update information and particulars (Section 7). A tissue bank must also make a “declaration of compliance” (Section 8), supported by a form in the First Schedule. These provisions are critical for establishing a regulator-facing compliance posture: the tissue bank must not only operate safely, but also demonstrate that it understands and will comply with the regulatory framework.
The Regulations also address specific notification triggers tied to the HBRA—such as notifications under section 35(3)(a) of the Act (Section 9). They further require reporting of serious adverse events and untoward occurrences. Sections 10–13 distinguish between notification by the tissue bank and notification under the Act for serious adverse events and untoward occurrences arising from removal of tissue. This structure is important for practitioners because it clarifies who must report, when, and for what categories of events.
3) Safety and quality controls before tissue is removed, supplied, or exported. Section 15 imposes requirements before tissue is removed, supplied, or exported. While the extract does not reproduce the full text of Section 15, the heading indicates a pre-release/pre-transfer compliance gate. In practice, such provisions typically require that tissue is handled and assessed according to safety and quality standards, and that the tissue bank has met all regulatory prerequisites before it can distribute tissue for research or export it.
Part 2 also includes confidentiality and traceability requirements. Section 16 protects the confidentiality of the donor’s information, which is central to ethical biomedical research and compliance with privacy expectations. Section 17 requires tracking of consent and the integrity of records—meaning tissue banks must maintain systems that can demonstrate that consent was obtained appropriately and that records remain accurate and unaltered. These provisions are often the backbone of audit readiness and are frequently scrutinised in investigations after adverse events.
4) Donor welfare and incidental findings. Section 18 requires attention to the safety and welfare of donors. This is a substantive obligation, not merely administrative: tissue banking must be conducted in a way that minimises risk to donors and ensures appropriate safeguards. Section 19 requires a policy on incidental findings. This is particularly relevant where research may reveal unexpected information about a donor’s health. A clear policy helps manage ethical duties, reduces uncertainty for staff, and supports consistent decision-making.
5) Special rules for tissue used in transplantation research. Part 3 (Sections 20–26) applies to “tissue for human tissue transplantation research.” It includes documentation requirements (Section 21) and tracking of information relevant to safety and quality of tissue (Section 22). Section 23 imposes additional requirements before tissue is released, supplied, or exported—again indicating a heightened gatekeeping function for transplantation-related research.
Part 3 also includes a notification duty by the recipient of human tissue (Section 24). This is a notable compliance expansion beyond the tissue bank: it recognises that recipients (researchers and research institutions) play an active role in ensuring safe use. Section 25 addresses management of tissue contamination, and Section 26 requires quality and safety management systems. Together, these provisions aim to ensure that transplantation-related research is supported by robust internal controls, not just by one-off safety checks.
6) Operational compliance: electronic systems, false information, and fees. Part 4 includes Section 27 on electronic systems, which likely governs how notifications and submissions are made (and ties to the “relevant website” definition). Section 28 prohibits false information, creating a compliance and enforcement lever for regulators. Section 29 provides for fees, with the Second Schedule setting out the fee structure. For practitioners, these provisions affect budgeting, administrative workflows, and the risk profile of submissions.
How Is This Legislation Structured?
The Regulations are organised into four parts.
Part 1 (Preliminary) contains the citation and definitions. Definitions in Section 2 are foundational: they determine the scope of regulated activities and the meaning of key terms such as “recipient,” “untoward occurrence,” and “human tissue transplantation.”
Part 2 (Tissue Banks Generally) sets out the baseline regulatory duties for tissue banks. It covers application of the Part (Section 3), notification and governance (Sections 4–14), pre-transfer safety requirements (Section 15), confidentiality and traceability (Sections 16–17), donor welfare and incidental findings (Sections 18–19), and reporting obligations for adverse events and untoward occurrences (Sections 10–13).
Part 3 (Tissue for Human Tissue Transplantation Research) adds enhanced requirements for a higher-risk category of research. It includes documentation and tracking (Sections 21–22), additional release/supply/export requirements (Section 23), recipient notification (Section 24), contamination management (Section 25), and quality and safety management systems (Section 26).
Part 4 (Miscellaneous) includes procedural and enforcement-related provisions: electronic systems (Section 27), prohibition of false information (Section 28), and fees (Section 29). The First Schedule contains the declaration of compliance form, and the Second Schedule contains the fee schedule.
Who Does This Legislation Apply To?
The Regulations apply primarily to tissue banks that conduct tissue banking activities for biomedical research in Singapore—particularly activities involving removal, storage, processing, supply, and export of human tissue. The obligations in Part 2 apply broadly to tissue banks generally, while Part 3 applies when the tissue is intended for human tissue transplantation research.
They also apply to recipients in the transplantation research context. Under Section 24, recipients (including researchers and research institutions) have notification duties when they receive human tissue from a tissue bank. Practitioners should therefore treat the Regulations as a shared compliance regime: tissue banks must meet operational and reporting obligations, and recipients must support safe use through their own administrative duties.
Why Is This Legislation Important?
The Tissue Banking Regulations are important because they operationalise the HBRA’s ethical and safety objectives into enforceable requirements. For practitioners, the Regulations provide the compliance blueprint for tissue banking—covering governance (principal person in charge, declarations), safety controls (pre-release requirements, contamination management), and accountability (notification of serious adverse events and untoward occurrences).
From a risk-management perspective, the definition of “untoward occurrence” is particularly significant. It includes not only clinical harms (death, life-threatening events, disability, hospitalisation) but also system failures such as misidentification or mix-ups, and biological risks such as transmission of communicable disease and congenital anomalies. This breadth means that compliance systems must be designed to detect and report both medical and operational failures.
Finally, the Regulations’ emphasis on traceability—tracking consent and record integrity, and tracking information relevant to safety and quality—supports auditability and regulatory oversight. In practice, these requirements help tissue banks and recipients respond quickly to incidents, demonstrate due diligence, and maintain public trust in biomedical research involving human tissue.
Related Legislation
- Human Biomedical Research Act 2015 (authorising Act; including section 63 and referenced provisions such as section 35(3) and section 27(3))
Source Documents
This article provides an overview of the Human Biomedical Research (Tissue Banking) Regulations 2019 for legal research and educational purposes. It does not constitute legal advice. Readers should consult the official text for authoritative provisions.